Collegium Pharmaceutical, Inc (COLL) stock
COLLNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 10/3045% below fair value
$24.95+0.14 (+0.56%)
Close on Nov 12, 2026Market cap $812.26MP/E 24.9Yield –
Collegium Pharmaceutical total assets
Total assets on the balance sheet at the end of each period.
Collegium Pharmaceutical's total assets was $2.10B at Sep 30, 2026. For fiscal 2025 it was $1.66B, down 0.4% from the year before. Over ten years it grew 32.7% a year on average. The highest annual figure on record is $1.66B in fiscal 2024.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.66B | -0.4% |
| FY2024 | Dec 31, 2024 | $1.66B | +45.5% |
| FY2023 | Dec 31, 2023 | $1.14B | -2.6% |
| FY2022 | Dec 31, 2022 | $1.17B | +69.7% |
| FY2021 | Dec 31, 2021 | $692.08M | +7.5% |
| FY2020 | Dec 31, 2020 | $643.84M | +110.2% |
| FY2019 | Dec 31, 2019 | $306.30M | +5.2% |
| FY2018 | Dec 31, 2018 | $291.25M | +114.8% |
| FY2017 | Dec 31, 2017 | $135.57M | -16.3% |
| FY2016 | Dec 31, 2016 | $162.02M | +65.8% |
| FY2015 | Dec 31, 2015 | $97.72M | +1819.8% |
| FY2014 | Dec 31, 2014 | $5.09M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $2.10B | +30.4% |
| Q2 FY2026 | Jun 30, 2026 | $2.14B | +34.1% |
| Q1 FY2026 | Mar 31, 2026 | $1.65B | +1.3% |
| Q4 FY2025 | Dec 31, 2025 | $1.66B | -0.4% |
| Q3 FY2025 | Sep 30, 2025 | $1.61B | -1.7% |
| Q2 FY2025 | Jun 30, 2025 | $1.59B | +51.2% |
| Q1 FY2025 | Mar 31, 2025 | $1.63B | +46.4% |
| Q4 FY2024 | Dec 31, 2024 | $1.66B | +45.5% |
| Q3 FY2024 | Sep 30, 2024 | $1.64B | +38.9% |
| Q2 FY2024 | Jun 30, 2024 | $1.05B | -13.2% |
| Q1 FY2024 | Mar 31, 2024 | $1.11B | -8.2% |
| Q4 FY2023 | Dec 31, 2023 | $1.14B | -2.6% |
| Q3 FY2023 | Sep 30, 2023 | $1.18B | -1.9% |
| Q2 FY2023 | Jun 30, 2023 | $1.21B | -2.5% |
| Q1 FY2023 | Mar 31, 2023 | $1.21B | -2.6% |
| Q4 FY2022 | Dec 31, 2022 | $1.17B | +69.7% |
| Q3 FY2022 | Sep 30, 2022 | $1.20B | +61.9% |
| Q2 FY2022 | Jun 30, 2022 | $1.25B | +74.5% |
| Q1 FY2022 | Mar 31, 2022 | $1.25B | +92.9% |
| Q4 FY2021 | Dec 31, 2021 | $692.08M | +7.5% |
| Q3 FY2021 | Sep 30, 2021 | $741.80M | +15.2% |
| Q2 FY2021 | Jun 30, 2021 | $713.74M | +10.3% |
| Q1 FY2021 | Mar 31, 2021 | $646.07M | +1.8% |
| Q4 FY2020 | Dec 31, 2020 | $643.84M | +110.2% |
| Q3 FY2020 | Sep 30, 2020 | $643.84M | +111.8% |
| Q2 FY2020 | Jun 30, 2020 | $646.87M | +114.5% |
| Q1 FY2020 | Mar 31, 2020 | $634.79M | +115.7% |
| Q4 FY2019 | Dec 31, 2019 | $306.30M | +5.2% |
| Q3 FY2019 | Sep 30, 2019 | $303.98M | -53.0% |
| Q2 FY2019 | Jun 30, 2019 | $301.58M | -55.2% |
| Q1 FY2019 | Mar 31, 2019 | $294.36M | -57.7% |
| Q4 FY2018 | Dec 31, 2018 | $291.25M | +114.8% |
| Q3 FY2018 | Sep 30, 2018 | $646.51M | +427.0% |
| Q2 FY2018 | Jun 30, 2018 | $673.33M | +440.8% |
| Q1 FY2018 | Mar 31, 2018 | $696.28M | +397.9% |
| Q4 FY2017 | Dec 31, 2017 | $135.57M | -16.3% |
| Q3 FY2017 | Sep 30, 2017 | $122.67M | – |
| Q2 FY2017 | Jun 30, 2017 | $124.52M | – |
| Q1 FY2017 | Mar 31, 2017 | $139.85M | – |
| Q4 FY2016 | Dec 31, 2016 | $162.02M | – |
See a number that looks wrong?